Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q1 2022 · 10-Q
Revenue$83.75M$83.75M−4.5% vs Q1 2021 Net Income-$13.07M-$13.07MN/M vs Q1 2021 EPS Diluted-$0.39-$0.39N/M vs Q1 2021 Gross Profit$48,496,000−12.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flow-$25,315,000N/M Free Cash Flowderived-$25,423,000N/M Margins · derivedGross margin57.9%−5.5 pt vs Q1 2021
Operating margin-12.0%−36.1 pt vs Q1 2021
Net margin-15.6%−33.5 pt vs Q1 2021
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end